Peru

Peru

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.5 (0.46 - 0.55) 2019 Modelled IHME
0.51 (0.47 - 0.57) 2018 Modelled IHME
0.52 (0.47 - 0.58) 2017 Modelled IHME
0.52 (0.47 - 0.57) 2016 Modelled IHME
0.52 (0.47 - 0.58) 2015 Modelled IHME
0.53 (0.48 - 0.58) 2014 Modelled IHME
0.53 (0.48 - 0.58) 2013 Modelled IHME
0.53 (0.48 - 0.58) 2012 Modelled IHME
0.54 (0.49 - 0.59) 2011 Modelled IHME
0.54 (0.49 - 0.60) 2010 Modelled IHME
0.55 (0.49 - 0.60) 2009 Modelled IHME
0.55 (0.50 - 0.61) 2008 Modelled IHME
0.55 (0.50 - 0.62) 2007 Modelled IHME
0.56 (0.50 - 0.62) 2006 Modelled IHME
0.56 (0.49 - 0.63) 2005 Modelled IHME
0.56 (0.50 - 0.63) 2004 Modelled IHME
0.56 (0.50 - 0.63) 2003 Modelled IHME
0.55 (0.50 - 0.62) 2002 Modelled IHME
0.55 (0.50 - 0.62) 2001 Modelled IHME
0.55 (0.50 - 0.62) 2000 Modelled IHME
0.55 (0.50 - 0.62) 1999 Modelled IHME
0.56 (0.50 - 0.62) 1998 Modelled IHME
0.56 (0.50 - 0.62) 1997 Modelled IHME
0.56 (0.50 - 0.62) 1996 Modelled IHME
0.56 (0.49 - 0.63) 1995 Modelled IHME
0.56 (0.49 - 0.62) 1994 Modelled IHME
0.55 (0.49 - 0.62) 1993 Modelled IHME
0.55 (0.49 - 0.62) 1992 Modelled IHME
0.55 (0.48 - 0.61) 1991 Modelled IHME
0.54 (0.48 - 0.61) 1990 Modelled IHME
1.51 (1.18 - 1.90) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.04 (0.03 - 0.05) 2019 Modelled IHME
0.04 (0.03 - 0.06) 2018 Modelled IHME
0.05 (0.03 - 0.06) 2017 Modelled IHME
0.04 (0.03 - 0.06) 2016 Modelled IHME
0.04 (0.03 - 0.05) 2015 Modelled IHME
0.04 (0.03 - 0.06) 2014 Modelled IHME
0.04 (0.03 - 0.06) 2013 Modelled IHME
0.04 (0.03 - 0.06) 2012 Modelled IHME
0.05 (0.03 - 0.06) 2011 Modelled IHME
0.05 (0.04 - 0.07) 2010 Modelled IHME
0.05 (0.04 - 0.07) 2009 Modelled IHME
0.06 (0.05 - 0.09) 2008 Modelled IHME
0.08 (0.06 - 0.10) 2007 Modelled IHME
0.09 (0.06 - 0.12) 2006 Modelled IHME
0.1 (0.07 - 0.13) 2005 Modelled IHME
0.1 (0.07 - 0.14) 2004 Modelled IHME
0.11 (0.08 - 0.14) 2003 Modelled IHME
0.11 (0.08 - 0.15) 2002 Modelled IHME
0.11 (0.08 - 0.15) 2001 Modelled IHME
0.12 (0.09 - 0.16) 2000 Modelled IHME
0.13 (0.10 - 0.17) 1999 Modelled IHME
0.15 (0.11 - 0.19) 1998 Modelled IHME
0.17 (0.12 - 0.21) 1997 Modelled IHME
0.18 (0.13 - 0.23) 1996 Modelled IHME
0.19 (0.14 - 0.24) 1995 Modelled IHME
0.19 (0.14 - 0.24) 1994 Modelled IHME
0.18 (0.14 - 0.24) 1993 Modelled IHME
0.18 (0.14 - 0.24) 1992 Modelled IHME
0.18 (0.13 - 0.24) 1991 Modelled IHME
0.18 (0.13 - 0.24) 1990 Modelled IHME
0.24 (0.16 - 0.35) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
40 (32 - 50) 2019 Modelled IHME
41 (32 - 50) 2018 Modelled IHME
41 (32 - 50) 2017 Modelled IHME
41 (33 - 51) 2016 Modelled IHME
42 (33 - 51) 2015 Modelled IHME
42 (33 - 51) 2014 Modelled IHME
42 (33 - 51) 2013 Modelled IHME
42 (34 - 51) 2012 Modelled IHME
43 (34 - 52) 2011 Modelled IHME
43 (34 - 52) 2010 Modelled IHME
43 (34 - 52) 2009 Modelled IHME
43 (35 - 52) 2008 Modelled IHME
44 (35 - 53) 2007 Modelled IHME
44 (36 - 53) 2006 Modelled IHME
44 (36 - 54) 2005 Modelled IHME
45 (36 - 54) 2004 Modelled IHME
45 (36 - 54) 2003 Modelled IHME
45 (36 - 54) 2002 Modelled IHME
46 (37 - 54) 2001 Modelled IHME
46 (37 - 55) 2000 Modelled IHME
46 (37 - 55) 1999 Modelled IHME
46 (37 - 55) 1998 Modelled IHME
46 (37 - 56) 1997 Modelled IHME
46 (37 - 55) 1996 Modelled IHME
46 (37 - 55) 1995 Modelled IHME
46 (37 - 55) 1994 Modelled IHME
46 (37 - 55) 1993 Modelled IHME
46 (37 - 55) 1992 Modelled IHME
46 (38 - 55) 1991 Modelled IHME
46 (38 - 56) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
73 2018 Survey/reported WHO/UNICEF
75 2017 Survey/reported WHO/UNICEF
79 2016 Survey/reported WHO/UNICEF
79 2015 Survey/reported WHO/UNICEF
78 2014 Survey/reported WHO/UNICEF
82 2013 Survey/reported WHO/UNICEF
81 2012 Survey/reported WHO/UNICEF
76 2011 Survey/reported WHO/UNICEF
74 2010 Survey/reported WHO/UNICEF
71 2009 Survey/reported WHO/UNICEF
79 2008 Survey/reported WHO/UNICEF
73 2007 Survey/reported WHO/UNICEF
66 2006 Survey/reported WHO/UNICEF
67 2005 Survey/reported WHO/UNICEF
68 2004 Survey/reported WHO/UNICEF
60 2003 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
84 2018 Survey/reported WHO/UNICEF
83 2017 Survey/reported WHO/UNICEF
89 2016 Survey/reported WHO/UNICEF
90 2015 Survey/reported WHO/UNICEF
88 2014 Survey/reported WHO/UNICEF
88 2013 Survey/reported WHO/UNICEF
95 2012 Survey/reported WHO/UNICEF
91 2011 Survey/reported WHO/UNICEF
93 2010 Survey/reported WHO/UNICEF
93 2009 Survey/reported WHO/UNICEF
93 2008 Survey/reported WHO/UNICEF
93 2007 Survey/reported WHO/UNICEF
94 2006 Survey/reported WHO/UNICEF
94 2005 Survey/reported WHO/UNICEF
92 2004 Survey/reported WHO/UNICEF
65 2003 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
0 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HBV testing policy
Pregnant women
HepB birth dose policy
Yes
Year of birth dose introduction
2000
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
No
% of substance use disorder facilities offering hepatitis treatment
No

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1 (0.80 - 1.24) 2019 Modelled IHME
0.99 (0.80 - 1.24) 2018 Modelled IHME
0.98 (0.79 - 1.23) 2017 Modelled IHME
0.98 (0.80 - 1.22) 2016 Modelled IHME
0.98 (0.79 - 1.22) 2015 Modelled IHME
0.99 (0.80 - 1.22) 2014 Modelled IHME
0.99 (0.80 - 1.22) 2013 Modelled IHME
0.99 (0.80 - 1.23) 2012 Modelled IHME
0.99 (0.80 - 1.23) 2011 Modelled IHME
0.99 (0.80 - 1.23) 2010 Modelled IHME
0.98 (0.79 - 1.22) 2009 Modelled IHME
0.96 (0.77 - 1.19) 2008 Modelled IHME
0.94 (0.75 - 1.15) 2007 Modelled IHME
0.91 (0.74 - 1.12) 2006 Modelled IHME
0.9 (0.72 - 1.10) 2005 Modelled IHME
0.89 (0.72 - 1.10) 2004 Modelled IHME
0.89 (0.72 - 1.09) 2003 Modelled IHME
0.88 (0.72 - 1.09) 2002 Modelled IHME
0.88 (0.71 - 1.09) 2001 Modelled IHME
0.88 (0.71 - 1.09) 2000 Modelled IHME
0.89 (0.72 - 1.09) 1999 Modelled IHME
0.9 (0.73 - 1.12) 1998 Modelled IHME
0.92 (0.75 - 1.15) 1997 Modelled IHME
0.94 (0.76 - 1.17) 1996 Modelled IHME
0.95 (0.77 - 1.17) 1995 Modelled IHME
0.95 (0.77 - 1.18) 1994 Modelled IHME
0.95 (0.77 - 1.17) 1993 Modelled IHME
0.94 (0.76 - 1.17) 1992 Modelled IHME
0.94 (0.76 - 1.17) 1991 Modelled IHME
0.93 (0.74 - 1.16) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
1.2 (0.40 - 1.60) 2014 Modelled Gower et al, 2014

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
8 (5 - 11) 2019 Modelled IHME
8 (5 - 11) 2018 Modelled IHME
8 (5 - 11) 2017 Modelled IHME
8 (5 - 11) 2016 Modelled IHME
8 (5 - 11) 2015 Modelled IHME
8 (5 - 11) 2014 Modelled IHME
8 (5 - 11) 2013 Modelled IHME
8 (5 - 11) 2012 Modelled IHME
8 (5 - 11) 2011 Modelled IHME
8 (5 - 11) 2010 Modelled IHME
8 (5 - 11) 2009 Modelled IHME
8 (5 - 11) 2008 Modelled IHME
8 (5 - 11) 2007 Modelled IHME
7 (5 - 11) 2006 Modelled IHME
7 (5 - 11) 2005 Modelled IHME
7 (5 - 11) 2004 Modelled IHME
7 (5 - 11) 2003 Modelled IHME
7 (5 - 10) 2002 Modelled IHME
7 (5 - 10) 2001 Modelled IHME
7 (5 - 10) 2000 Modelled IHME
7 (5 - 10) 1999 Modelled IHME
7 (5 - 10) 1998 Modelled IHME
7 (5 - 10) 1997 Modelled IHME
7 (5 - 10) 1996 Modelled IHME
7 (4 - 10) 1995 Modelled IHME
7 (4 - 10) 1994 Modelled IHME
7 (4 - 10) 1993 Modelled IHME
7 (4 - 10) 1992 Modelled IHME
7 (4 - 10) 1991 Modelled IHME
7 (4 - 10) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HBV testing policy
Pregnant women
HepB birth dose policy
Yes
Year of birth dose introduction
2000
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
No
% of substance use disorder facilities offering hepatitis treatment
No

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
0.5 (%)
2019
(0.46 - 0.55(%))
IHME
HCV (RNA/cAg+)
1 (%)
2019
(0.8 - 1.24(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
846
2019
(581 - 1,186)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
887
2019
(563 - 1,334)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.04 (%)
2019, latest modelled
(0.03 - 0.05(%))
IHME

Prevalence PWID

No data available

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
73 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

HCV
0
2016
(0 - 0)
Harm Reduction International, 2016
Eligible for HBV generic medicines
Eligible for HCV generic medicines